Bristol Still Committed To Yervoy In Prostate Cancer, Despite Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Yervoy misses overall survival endpoint in Phase III castration-resistant prostate cancer study, but it does show activity, particularly in patients with less advanced disease.